NOBIVAC® DHPPi

For the active immunisation of dogs against canine distemper, infectious canine hepatitis, canine parvo virus disease and canine parainfluenza virus infection.

FOR ANIMAL USE ONLY

Nobivac® DHPPi

Lyophilisate and solvent for suspension for injection

Reg. No. G2377 (Act 36/1947)

Namibia Reg. No. V97/24.1/900 [NS2]

Only for use by or under the supervision of persons registered in terms of or authorised in terms of Section 23 (1) (c) of the Veterinary and Para-veterinary Professions Act, 1982 (Act no. 19 of 1982).

INDICATIONS

For the active immunisation of dogs against canine distemper, infectious canine hepatitis, canine parvovirus disease and canine parainfluenza virus infection.

COMPOSITION

Each 0,5 mℓ vial of the lyophilised substance contains live, attenuated strains of:

  • canine distemper virus (CDV) not less than 104 TCID50,
  • canine adenovirus type 2 (CAV2) not less than 104 TCID50,
  • canine parvovirus (CPV) not less than 107 TCID50 and
  • canine parainfluenza virus (CPI) not less than 105,5 TCID50.

Each vial contains a single dose for reconstitution.

STORAGE INSTRUCTIONS

  • Store between 2 °C – 8 °C in a refrigerator.
  • Do not freeze.
  • Protect from light.
  • Avoid prolonged or repetitive exposure to high ambient temperatures.
  • Allow the vaccine to gradually reach room temperature (20 °C to 25 °C) prior to use.

WARNINGS

  • Following initial vaccination, dogs should not be exposed to infection for at least 14 days.
  • Experience has shown that maternal parvovirus antibody status of the puppies in a litter varies greatly and reliance should not be placed on serological examination of the bitch alone.
  • Accidental self-injection may lead to a severe allergic reaction. Consult a physician and make this leaflet available.
  • Do not store partially used containers for future use and use the entire contents once opened.
  • Dispose of any unused vaccine and all empty vaccine containers according to local waste disposal regulations after vaccination.
  • KEEP OUT OF REACH OF CHILDREN, UNINFORMED PERSONS AND ANIMALS.
  • Although this vaccine has been extensively tested under a large variety of conditions, failure thereof may ensue as a result of a wide range of reasons. If this is suspected, seek veterinary advice and notify the registration holder.

PRECAUTIONS

  • Only healthy dogs and puppies should be vaccinated.
  • Avoid intravenous injection.
  • Observe aseptic precautions. Ensure that all vaccination equipment (needles, syringes, etc.) is clean and sterile prior to and during use.
  • Avoid contamination of the vaccine with traces of disinfectant and spirits.
  • As with all vaccines, hypersensitivity or anaphylactic reactions may occur.
  • It is good vaccination practice when handling the vaccine to avoid contact with the eyes, hands and clothing.

DIRECTIONS FOR USE – USE ONLY AS DIRECTED

Vaccination Programme

The following recommendations are included since it is likely that immunisation with Nobivac® DHPPi will form part of a more comprehensive vaccination programme.

At 4 to 6 weeks:                         Nobivac® Puppy DP (G2323).

Then, 3 to 4 weeks later:         Nobivac® DHPPi with or withoutNobivac® Lepto (G2200).

And 3 to 4 weeks thereafter: Nobivac® DHPPi and Nobivac® Rabies* (G2207) or Nobivac®    

                                                          RL* (G2199) if Nobivac® Lepto (G2200) was used previously.

*Nobivac® Rabies (G2207) and Nobivac® RL (G2199) only to be used from 12 weeks of age.

Revaccination

It is recommended that dogs be revaccinated against:

  1. Canine distemper, canine hepatitis, canine parvovirus infection – every 3 years.
  2. Canine parainfluenza virus infection – every year.
  3. Rabies – every 3 years (it may be modified to comply with local regulations).

DOSAGE AND ADMINISTRATION

The contents of 1 vial of reconstituted vaccine should be injected subcutaneously.

Reconstitute the Nobivac® DHPPi immediately prior to use by adding the contents of 1 vial (1,0 mℓ) of any of the following: 

Nobivac® Lepto (G2200), Nobivac® Rabies (G2207) or Nobivac® Solvent.

PRESENTATION

The vials are of hydrolytical Type I glass (Ph. Eur.) and are closed with halogenated butyl rubber stoppers (Ph. Eur.) and sealed with coded aluminium caps. 

Vials are packed in in polyethylene terephthalate (PET) trays or in cardboard boxes containing 10 or 50 single dose vials.

REGISTRATION HOLDER                                                      

Intervet South Africa (Pty) Ltd.                                       

20 Spartan Road, Spartan                                                             

1619, RSA                                                                                 

Tel: +27 (0) 11 923 9300                                                        

E-mail: msdahza@msd.com                                                         

www.msd-animal-health.co.za                                                                                                                                                                        

DATE OF PUBLICATION OF PACKAGE INSERT

03 September 2014

Zimbabwe Reg. No. E97/80.23.15/9470
Veterinary Classification: 802315
Distribution Category: PP